Your using an unsupported browser. Please update to a modern browser for a better experience.
Request a free consultation with Clario’s industry-leading science team
Design a study that’s optimized and compliant, and collect data that’s meaningful, accurate and higher-quality when you engage our teams early in your trial planning.
Leverage Clario’s expertise and experience to strengthen your studies
27,000
trials supported
60%
of 2019-2022 FDA approvals
80+
key opinion leaders
200+
indications across all TAs
Clario science teams have a track record of supporting 27,000+ clinical trials, underscoring their proficiency in navigating this complex landscape. Engaging them early in your trial planning means tapping into their wealth of practical trial experience and regulatory excellence, optimizing your study right from the start.
Early engagement with Clario’s science team is key, given their expertise in anticipating unforeseen regulatory obstacles and identifying pathways to optimize clinical trial design and execution.
- Clario’s scientists not only understand the latest guidelines but are also actively involved in shaping regulatory guidance. They have played a significant role in the development of recent blood pressure guidelines, the IQCSRC prospective cardiac safety study and the FDA’s guidance on patient-focused drug development using eCOA based endpoints.
- Their scholarly record includes peer-reviewed publications and participation in conferences and consortia – further demonstrating their dedication to sharing the most current evidence with industry stakeholders, researchers and regulators.
Our scientific team is well versed in clinical trial design, reporting and analysis to ensure appropriate clinical efficacy and safety endpoints for sponsors.
- Engaging with our scientists early is strategically valuable in developing an efficient study design, identifying data collection methods and refining existing protocols to balance robust assessments with patient burden.
-
Clario’s advice is based on trial-tested and experience-based approaches that are driven by years of experience and tens of thousands of clinical studies.
Our science teams help determine an appropriate schedule of assessments, ensuring that data collection is sufficient to meet endpoint requirements without excessive patient burden or sponsor cost.
- Our global network of experienced physicians provides centralized overread of imaging, cardiac safety and respiratory data, with a strategic focus on minimizing inter- and intrareader variability.
- They leverage innovative technologies to capture and adjudicate data digitally, overreading with state-of-the-art tools to maximize accuracy and precision.
- Comprehensive site support is provided throughout the study, from start-up to final data transfer, to ensure the highest data quality.
-
Our science team works with sponsors to optimize data quality in eCOA trials using the most suitable assessments, ensuring good instrument design and recommending the appropriate data capture technologies for the patient population.
Early engagement with Clario’s science team is key, given their expertise in anticipating unforeseen regulatory obstacles and identifying pathways to optimize clinical trial design and execution.
- Clario’s scientists not only understand the latest guidelines but are also actively involved in shaping regulatory guidance. They have played a significant role in the development of recent blood pressure guidelines, the IQCSRC prospective cardiac safety study and the FDA’s guidance on patient-focused drug development using eCOA based endpoints.
- Their scholarly record includes peer-reviewed publications and participation in conferences and consortia – further demonstrating their dedication to sharing the most current evidence with industry stakeholders, researchers and regulators.
Our scientific team is well versed in clinical trial design, reporting and analysis to ensure appropriate clinical efficacy and safety endpoints for sponsors.
- Engaging with our scientists early is strategically valuable in developing an efficient study design, identifying data collection methods and refining existing protocols to balance robust assessments with patient burden.
-
Clario’s advice is based on trial-tested and experience-based approaches that are driven by years of experience and tens of thousands of clinical studies.
Our science teams help determine an appropriate schedule of assessments, ensuring that data collection is sufficient to meet endpoint requirements without excessive patient burden or sponsor cost.
- Our global network of experienced physicians provides centralized overread of imaging, cardiac safety and respiratory data, with a strategic focus on minimizing inter- and intrareader variability.
- They leverage innovative technologies to capture and adjudicate data digitally, overreading with state-of-the-art tools to maximize accuracy and precision.
- Comprehensive site support is provided throughout the study, from start-up to final data transfer, to ensure the highest data quality.
-
Our science team works with sponsors to optimize data quality in eCOA trials using the most suitable assessments, ensuring good instrument design and recommending the appropriate data capture technologies for the patient population.
Involve Clario scientists early to reduce costly amendments
More than half of all protocols will have at least one substantial amendment. With one change to your Phase III trial protocol averaging $535,000, these costs can add up quickly, on top of the significant delays to study timelines. What’s worse is that nearly half of these amendments were avoidable and originated from imperfect protocol design. Therefore, ~25% of all protocols include at least one avoidable amendment.*
Engaging Clario scientists early in clinical trial planning enables the development of robust protocols that reduce the likelihood of expensive amendments that prolong timelines.
*Getz et al., 2016
Percentage of all protocols with at least one avoidable and substantial amendment originating from imperfect study design.
Access peer-to-peer feedback and scientific discussion across all therapeutic areas
Request a free initial consultation with our scientists.